New Delhi: Billionaire Mukesh Ambani’s group is getting into genetic mapping, looking to make a healthcare trend led by disruptive US startups like 23andMe more affordable and widespread in India’s growing consumer market, according to Economic Times.
Within weeks, the energy-to-ecommerce conglomerate will roll out a comprehensive Rs 12,000 ($145) genome sequencing test, Ramesh Hariharan, chief executive officer of Strand Life Sciences Pvt., which has developed the product was quoted as saying. Reliance Industries acquired the Bengaluru-based firm in 2021 and now owns about 80% of it.
The genome test, which is about 86% cheaper than other offerings available locally, can reveal a person’s predisposition to cancers, cardiac and neuro-degenerative ailments as well as identify inherited genetic disorders, he was quoted as saying.
Singapore/Bhubaneswar: Chief Minister Mohan Charan Majhi, who is on a four-day visit to Singapore, on…
Cuttack: The toll in mango kernel incident in Odisha’s Kandhamal rose to three as another…
New Delhi: On a day when Congress demanded the resignations of Amit Shah and Manipur Chief…
Bhubaneswar: In the wake of a controversy triggered by reports about a boy being projected…
New Delhi: A contestant appearing to mock actor Deepika Padukone's battle with depression on Samay…
Cuttack: Senior BJP leader and former minister Samir Dey breathed his last on Monday while…
Mahayuti vs Maha Vikas Aghadi - it's an electoral Mahabharat in Maharashtra, albeit a lot…
New Delhi: Former Delhi minister and senior AAP leader Kailash Gahlot, who resigned from the…